Skip to main content

Pfizer Broadens License to Inpharmatica s PharmaCarta Platform

NEW YORK, Jan. 25 (GenomeWeb News) - Inpharmatica said today that it has expanded an informatics agreement with Pfizer that the companies initiated in 2000.

 

Under the expanded agreement, Pfizer will use four components of Inpharmatica's PharmaCarta technology platform. These components are in addition to Pfizer's current subscription to Biopendium, which the company first licensed five years ago.

 

Pfizer will gain access to Inpharmatica's StarLite database of curated medicinal chemistry information; to its DrugStore database of all known drugs, linked with their targets; and to the Admensa ADME prediction platform.

 

Inpharmatica will also use its proprietary PharmaCarta technology for a druggability assessment study.

 

Financial terms of the new agreement were not disclosed.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.